KDST Stock Overview
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kadimastem Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪4.89 |
| 52 Week High | ₪10.40 |
| 52 Week Low | ₪4.50 |
| Beta | 0.60 |
| 1 Month Change | -3.47% |
| 3 Month Change | -14.59% |
| 1 Year Change | -41.74% |
| 3 Year Change | -83.19% |
| 5 Year Change | -95.29% |
| Change since IPO | -98.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| KDST | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 2.5% | -1.8% | -3.1% |
| 1Y | -41.7% | 4.7% | 9.5% |
Return vs Industry: KDST underperformed the IL Biotechs industry which returned 4.6% over the past year.
Return vs Market: KDST underperformed the IL Market which returned 10% over the past year.
Price Volatility
| KDST volatility | |
|---|---|
| KDST Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: KDST's share price has been volatile over the past 3 months.
Volatility Over Time: KDST's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 31 | Asaf Shiloni | www.kadimastem.com |
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Kadimastem Ltd Fundamentals Summary
| KDST fundamental statistics | |
|---|---|
| Market cap | ₪20.52m |
| Earnings (TTM) | -₪12.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs KDST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KDST income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪12.01m |
| Earnings | -₪12.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -115.0% |
How did KDST perform over the long term?
See historical performance and comparison